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Abstract
The Centre for the Clinical Application of Particles’ Laser-hybrid Accelera-
tor for Radiobiological Applications (LhARA) facility is being studied and
requires simulation of novel accelerator components (such as the Gabor lens
capture system), detector simulation and simulation of the ion beam interac-
tion with cells. The first stage of LhARA will provide protons up to 15 MeV
for in vitro studies. The second stage of LhARA will use a fixed-field accel-
erator to increase the energy of the particles to allow in vivo studies with
protons and in vitro studies with heavier ions.
BDSIM, a Geant4 based accelerator simulation tool, has been used to
perform particle tracking simulations to verify the beam optics design done
by BeamOptics and these show good agreement. Design parameters were
defined based on an EPOCH simulation of the laser source and a series
of mono-energetic input beams were generated from this by BDSIM. The
tracking results show the large angular spread of the input beam (0.2 rad) can
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be transported with a transmission of almost 100% whilst keeping divergence
at the end station very low (< 0.1 mrad). The legacy of LhARA will be the
demonstration of technologies that could drive a step-change in the provision
of proton and light ion therapy (i.e. a laser source coupled to a Gabor lens
capture and a fixed-field accelerator), and a system capable of delivering a
comprehensive set of experimental data that can be used to enhance the
clinical application of proton and light ion therapy.
Keywords: Radiobiology, Laser, Ion, Beam
1. Introduction
Cancer is a major cause of death with 17 million new cases each year glob-
ally and incidence rates predicted to increase to 27.5 million new cases per
year by the year 2040 [1]. Radiotherapy is an important treatment modal-
ity and in England, 27% of patients received radiotherapy as part of their
primary cancer treatment during 2013–2014 [2]. Conventional radiotherapy
uses X-ray photons to deliver dose to the tumour, causing damage that can
kill the cancerous cells. The dose deposition distribution of X-rays as a func-
tion of depth within the patient is exponential. This means that treating
tumours that are deep within the patient will deliver a higher dose to the
organs and sensitive tissues located in front of the tumour than the dose de-
livered to the tumour. This can be mitigated by using a number of different
treatment fields, i.e. several treatments from different angles, to reduce the
dose given to organs surrounding the tumour. However, this is an important
issue for tumours that are close to critical structures such as the brain and
spinal cord and for infants where dose to healthy tissue, organs and bone can
lead to developmental issues and a higher probability of causing secondary
malignancies later in life. Protons and other light ion beams are attractive
options for radiotherapy as, unlike photons, there is little (ions) or no (pro-
tons) dose deposited beyond the distal tumour edge. In addition, as the dose
is primarily deposited in the Bragg peak region near the maximum range
of the beam for a given energy, treatment can be conformed to the tumour
volume by using beams of different energies, which is referred to as a spread
out Bragg peak (SOBP). The effect of using an SOBP is to increase the dose
to tissue and organs in front of the tumour but sensitive organs behind the
tumour would still only receive very little dose compared to treatment with
photons. For an SOBP, the dose given to tissue in front of the tumour de-
2
pends on the number of different beam energies needed to deliver the required
dose to the tumour and on the depth of the tumour. By carefully choosing
the treatment fields, dose to sensitive organs can be reduced compared to an
equivalent treatment with photons, thus improving patient outcomes. See
Figure 1 in [3] for an example of the dose depth profile of an SOBP and a
photon dose profile for comparison.
The importance of proton beam therapy has been recognised by NHS,
UK, with the creation of two new proton beam centres to treat teenagers
and young adults with cancer and other patients with certain cancers such
as highly complex brain, head and neck cancers [4]. However, the conven-
tional methods used to produce proton beams at energies suitable for clinical
use are expensive and require relatively large accelerators and a beam deliv-
ery system that requires precisely positioning large magnets in an arc such
that the beam can be rotated around the patient. In comparison, X-ray ma-
chines are compact and relatively cheap allowing them to be installed in a
hospital room instead of requiring a dedicated facility. It has been proposed
by [5], [6] and [7] that laser-driven ion beams could provide an alternative to
conventional accelerator facilities for radiotherapy applications. Laser-driven
ion beams can provide very high dose rates (from several hundred Gy/s to
more than 109 Gy/s) and can produce carbon ions in addition to protons.
Studies have indicated that radiotherapy with ultra-high dose rates can re-
sult in improved normal tissue sparing for the same total treatment dose,
see [8] and [9]. Thus, laser-driven ion beams provide a very promising alter-
native to conventional accelerators. However, issues such as the maximum
energy achievable, large beam divergence, large energy spread and shot-to-
shot variations need to be addressed.
Another important issue for proton beam therapy is that treatment plan-
ning assumes that the relative biological effectiveness (RBE) is a factor of
1.1 [10], which means a lower dose of protons is needed to produce the same
effect than if photons were used. However, this is an average value that can
vary with several physical and biological parameters including particle type,
dose, dose rate, linear energy transfer and biological endpoint. A number
of other studies have also shown there can be significant variation in RBE,
see [11], [12] and [13]. A detailed systematic study of the biophysical effects
of the interaction of protons, under different physical conditions, with dif-
ferent tissue types would provide important information on RBE variation
and could enable enhanced treatment planning. Such studies are especially
needed in the case of heavier ion beam radiotherapy. A number of studies
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done in the past have used laser-driven ion beams to investigate radiobiolog-
ical effects, see for example [14], [15], [16], [17], [18] and [19]. More recent
projects (e.g. A-SAIL, ELI and SCAPA) will also study radiobiological effects
using laser-driven ion beams and will address various technological issues, see
for example [20], [21], [22], [23] and [24].
The Centre for the Clinical Application of Particles (CCAP) at Impe-
rial College London is composed of clinical oncologists, medical physicists,
accelerator and instrumentation scientists and radiobiologists. One focus of
the CCAP’s programme is the Laser-hybrid Accelerator for Radiobiologi-
cal Applications (LhARA). LhARA will prove the principal of certain novel
technologies for future therapy facilities by developing a proton and light
ion beam radiobiology facility for in vitro and in vivo studies, which will
contribute to the vibrant field of laser-driven ion beam radiobiology. Con-
ventional proton and ion sources produce particles with energies of tens of
keV/u. At such low energies, the Coulomb repulsion between the parti-
cles that make up the beam limit the beam-current that can be captured
and accelerated. Laser accelerated ions can be generated at higher energies
(1×104 keV or more) and therefore do not suffer the same limitations, allow-
ing injection into a strong focusing particle capture system. One issue with
the laser-driven ion beam is that it has a significant divergence making it
very difficult to capture using conventional focusing elements. LhARA will
use a Gabor lens, which is a confined-plasma focusing device, to improve the
capture of the laser-driven ion beam. The beam can then be manipulated
using conventional magnets and injected into a fixed-field accelerator (FFA),
which has a large acceptance, that will accelerate the particles to energies
suitable for in vivo experiments. Using these novel technologies for LhARA
will make it possible to deliver multiple ion species from a single source, while
overcoming the beam divergence issues of laser-driven ion beams, to provide
a facility that can produce intense beams (and thus ultra-high dose rates) of
protons and ions from helium to carbon to deliver a definitive programme
of radiobiology. The legacy of this programme will be the demonstration of
technologies that can drive a step-change in the provision of proton and light
ion therapy (i.e. a laser source coupled to a Gabor lens capture and an FFA),
and a system capable of delivering a comprehensive set of experimental data
that can be used to enhance the clinical application of proton and light ion
therapy.
This paper will present the design concept of the first stage of LhARA
that will use the laser source coupled to a Gabor lens capture system and
4
a conventional beam-line (i.e using normal conducting magnets) to deliver
proton beams (up to 15 MeV) suitable for in vitro studies only. The second
stage of LhARA that will deliver protons for in vivo experiments and heavier
ion beams for in vitro experiments requires injection into an FFA that will
increase the momentum by a factor of three (i.e. up to a kinetic energy of
127 MeV for protons and 33 MeV/u for carbon 6+ ions). Initial tracking
simulations of the first stage of LhARA using BDSIM [25] and [26], which
is an accelerator simulation tool based on Geant4 [27] (the version used in
these simulations is 10.4.1), have been performed to verify the optics design
of the beam-line (done using BeamOptics [28]) and to determine the energy
deposition profile in the end station to confirm that the 15 MeV laser cut-off
energy is suitable.
2. The Laser-Hybrid Accelerator for Radiobiological Applications
(LhARA)
The first stage of LhARA will use a laser-driven ion beam for detailed sys-
tematic studies of in vitro radiobiology. Figure 1 shows the LhARA beam-line
as implemented in BDSIM, which consists of: a capture system; upstream
matching; a vertical 90◦ bend that provides energy and ion selection; down-
stream matching; and the end station which includes a vacuum window and
a cell culture plate. The capture section is based on Gabor lenses that pro-
vide compact capture and focusing of the large divergence and large energy
spread of the laser-driven ion beam. The upstream matching section is a
quadrupole focusing channel used to match the beam from the capture sec-
tion to the section that performs energy and ion selection. Two 45◦ dipole
bends and collimators are used to select particles of the required momentum.
The gap between the two dipoles is large enough to place a Wien filter for
velocity selection, which would allow particle species selection in the case
that separating particle species based on momentum is not effective enough.
The downstream matching section then transports the beam such that at
the entrance of the end station (i.e. the vacuum window) the beam has a
very small divergence (< 10−4 rad), occupies the 30 mm diameter aperture
and has an energy spread of ±2%.
2.1. Laser source
The laser uses the principle of target normal sheath acceleration to gen-
erate an ion beam. Figure 2 shows the basic principle where a high intensity
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Figure 1: The LhARA beam-line as implemented in BDSIM. The direction of the laser
beam used to generate the beam is marked and the various sections are annotated.
laser pulse is fired at a thin target at an angle of 45◦ which causes an ion
beam (consisting of protons and carbon ions) to be generated from the con-
taminants on the back surface of the target. See [29] for a more detailed
explanation of sheath acceleration. Using this method generates a high-
intensity beam composed of a variety of ions but with a very large energy
spread and large angular divergence. A typical energy and angle distribution
of a proton beam with a cut-off energy of 15 MeV, from an EPOCH [30]
simulation, is shown in Figure 3.
The EPOCH simulation was used to determine the design parameters for
the optics design, which are given in Table 1. These were used to generate a
Gaussian distributed beam of 104 protons using BDSIM in order to compare
the tracking simulations with the optics design of the LhARA beam-line. The
initial particle distribution used in the tracking simulations is shown in Fig-
ures 4, 5 and 6. The combination of a small Twiss beta and relatively large
emittance means the beam has a small spot size but a very large divergence
(the opening angle is 0.2 rad).
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Figure 2: Schematic diagram illustrating the principle used to generate the ion beam.
Alpha 0
Beta 71× 10−6 m
Emittance 4× 10−8pim rad
Kinetic energy 15 MeV
Table 1: Beam parameters used to generate an input beam for tracking with BDSIM. The
parameters alpha and beta are the Twiss parameters. Since the beam is assumed to be
initially cylindrically symmetric, beta, alpha and the emittance are the same for both the
x and y planes.
2.2. Capture
The ion beam generated from the laser target is captured by a series of
Gabor lenses. A Gabor lens uses a confined electron plasma to produce an
electro-static focusing field. Figure 7 shows the key components of the Gabor
lens. The magnetic field produced by the solenoid coils causes the electrons
to exhibit spiral trajectories parallel to the axis of the lens, thus confining
them in the radial direction. The voltage applied to the anode generates the
space charge and the field between the anode and the ground plates at the
ends confines the electron cloud in the longitudinal direction.
Details of the Gabor lens and its application to the capture of laser-driven
ion beams for cancer therapy is described in [31] and shows the expected
opening angle of the laser source captured by the Gabor lens (for 200 MeV
protons and 5% energy spread) to be around 76 mrad which is better than
a similar solenoid solution (requiring a 10 T field), e.g. in [32], that would
7
Figure 3: Distribution of energy and angle from a proton beam simulation using EPOCH
with a cut-off energy of 15 MeV. In this simulation 0 degrees is the direction of the laser.
only capture 40 mrad. At these clinically relevant energies, the Gabor lens is
expected to provide better performance without the need for strong magnetic
fields and would be significantly cheaper. Thus, it is important that LhARA
demonstrates the capability of using the Gabor lens to capture a laser-driven
ion beam.
A prototype of the lens has been built and tested using a 1 MeV proton
beam at the Surrey Ion Beam Centre, see [33]. Following these tests the
prototype has been upgraded and is now being recommissioned at Imperial
College London, UK. It is planned that the upgraded lens will be tested using
a laser-driven ion beam also at Imperial College London.
2.3. Beam transport
The beam transport section includes the upstream matching, 90◦ vertical
bend and the downstream matching, all of which use conventional quadrupole
and dipole magnets. The 90◦ bend is performed using two 45◦ dipole magnets
where the drift between the magnets is long enough for collimators and an
optional Wien filter to be inserted. The dispersion created by the dipoles
can be used in conjunction with slit collimators to select only particles of a
8
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Figure 4: Distribution of the x phase space of the input beam used in the BDSIM simu-
lations.
particular momentum, with the width of the slit determining the range of
momenta selected. The momentum spectrum of carbon ions produced by
the target is expected to be lower than that of protons, allowing separation
of protons from carbon ions purely based on momenta. If however there
is an overlap in the momentum spectrum of protons and other ion species
there is sufficient space between the dipoles to include a Wien filter. This
allows the selection of particles based on their velocity, by using electrostatic
and magnetic deflectors and a collimator. Work is ongoing to understand
better the momentum spectrum of the ions produced by the target taking
into account fragmentation effects to verify that selecting a pure sample of
protons can be achieved.
2.4. End station
The beam is delivered vertically into the end station, which is where
the cells will be irradiated. Vertical delivery of the beam allows the use of
conventional cell culture plates, such as that shown in Figure 8, that provide
breathable wells where the cell sample is grown on the bottom of a well filled
with cell nutrient liquid. Such cell culture plates are available in a variety of
sizes and the final choice will be dependent on the numbers of cell samples
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Figure 5: Distribution of the y phase space of the input beam used in the BDSIM simu-
lations.
required for a particular cell type and the configuration of the beam will be
matched such that the whole area of the well will be irradiated.
Since the beam energy is low, any unnecessary material in the beam path
may prevent the beam reaching the cell layer. Increasing the beam energy
is possible but would require a more costly laser system. Figure 9 shows
the current schematic design of the end station and the materials in the
path of the beam. The thickness of the cell culture plate was taken from
measurements of the one shown in Figure 8. This could be made thinner by
manufacturing custom cell culture plates instead of using off-the-shelf ones,
if this was a limiting factor. For the simulation only the area of the nominal
beam aperture was considered, i.e. a cylinder 30 mm in diameter, since the
expected beam divergence is very small (< 10−4 rad). The scintillating fibre
layer will be used to monitor the beam uniformity in real time, pulse-by-
pulse. Using two layers would allow determining the transverse dose profile
delivered to each cell sample. A prototype detector that can provide a 2D
beam intensity profile measurement with a position resolution of 250µm is
currently under development. At high beam intensities the life-time of a
fibre based detector could be an issue and this will be investigated by testing
the prototype with a laser-driven ion beam. The possibility of using multiple
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Figure 6: Distribution of the x-y profile of the input beam used in the BDSIM simulations.
layers (in an offline measurement without the cell culture plate) to accurately
predict the dose deposition profile in the cell layer is also being investigated.
For absolute dose calibration, conventional diagnostics used for laser-
driven ion beams, such as radiochromic films (e.g. Gafchromic film) and
nuclear track detectors (e.g. CR-39), could be used. By placing the detector
layer (i.e. either the Gafchromic film or the CR-39 layer) at the position of
the cell layer with material in front identical to the base of the cell culture
plate, the dose that would be delivered to the cell layer can be measured. The
issue with using such detectors is that these measurements would be done in
a separate run to the cell irradiations, meaning variations in beam conditions
would affect the actual dose delivered to the cells. However, it may be possi-
ble to correct for such variations by correlating the intensity profile measure-
ments from the scintillating fibre layer with the absolute dose measurements.
Calibration of the films is another important issue and would require tests
at a facility where the delivered dose can be accurately determined. Other
groups have performed similar experiments, see for example [34] and [35].
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Figure 7: Schematic diagram of the Gabor lens.
Figure 8: A typical six well cell culture plate.
3. Results
Figures 10 and 11 show a comparison of the beta function (which gives the
beam envelope as a function of distance along the beam-line) from the beam
optics design, which was performed using BeamOptics, and the beta values
after each element in the BDSIM simulation. Figure 10 gives the comparison
for the capture section and shows good agreement between the calculated
beta from BeamOptics and the beta calculated from the particle distributions
from the BDSIM tracking simulations. The Gabor lens was implemented in
BDSIM using a solenoid of equivalent focusing strength. In the future, the
Gabor lens will be simulated to produce a 3-D electro-magnetic field map
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Figure 9: Design of the end station simulated with BDSIM.
that can then be used for tracking in BDSIM.
Figure 11 shows the comparison of the beta function from BeamOptics
and BDSIM for the beam transport section. The beta functions show good
agreement and at the end of the transport section the beta function is flat,
which means the divergence of the beam in the end station will be small.
Figure 12 zooms in on the beta functions in the bending region. There
can be seen a mismatch in the beta functions in the x-direction. This is
probably due to differences in the treatment of edge focusing in BeamOptics
and BDSIM and is currently under investigation, though this does not affect
the beam significantly since the beta functions are in good agreement down-
stream with the mismatch in the beta function at the end of the transport
section being 7% in the x-direction and 1% in the y-direction. This translates
to a difference in the beam envelope of 3% in the x-direction and less than
0.6% in the y-direction.
The distribution of the beam at the entrance of the end station, extracted
from the BDSIM simulation, is shown in Figures 13, 14 and 15. The impor-
tant result here is that the divergence of the beam in the end station is very
small, i.e. < 10−4 and that the transmission is 99.9% for a simulation run of
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Figure 10: Comparison of the beta function from the beam optics design code BeamOptics
and the beta values extracted from the BDSIM simulation for the capture section.
104 particles. The x-y profile of the beam is similar to that of the input beam
and will determine the dose distribution over the cell sample. Work is ongo-
ing to investigate the effect of the non-uniform beams produced by the laser
on the beam distribution at the end station. However, the aim for LhARA
is to measure this pulse-by-pulse using the scintillating fibre detector so that
the actual transverse dose profile delivered to the cells can be determined.
BDSIM was used to extract the energy deposited in the different material
layers, which is shown in Figure 16 for three different beam energies. This
shows that a beam with kinetic energy of 10 MeV does not reach the cell layer
but the 12 MeV beam has the Bragg peak (i.e. where most of the energy is
deposited) at the position of the cell layer. However, this would not allow
investigating the radiobiological effect of irradiating a sample located before
the Bragg peak. Thus the design kinetic energy of 15 MeV has been chosen
since it will also contain a significant number of particles in the range 10–
15 MeV allowing irradiation with a variety of energies. The energies of the
particles entering and exiting the cell layer for a 15 MeV proton beam is given
in Figure 17. This shows the mean energy of particles entering the cell layer
is 8.8 MeV with an energy spread (caused by stochastic effects) of 0.14 MeV.
From the two plots in Figure 17 the energy deposited in the cell layer was
calculated to be 1.7 GeV (1.2 × 10−5 Gy) for a bunch of 104 protons. For
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Figure 11: Comparison of the beta functions from BeamOptics and BDSIM for the beam
transport section.
the 12 MeV beam the energies of the particles entering and exiting the cell
layer is given in Figure 18. In this case the energy deposited in the cell layer
is 4.5 GeV (3.1 × 10−5 Gy) for 104 protons, which is much higher than for
the 15 MeV beam, as expected, since the cell layer is located in the Bragg
peak for the 12 MeV beam. However, the actual number of protons per pulse
for LhARA could be significantly higher than this, 106–109 protons. Thus
the dose per pulse could be up to 1.2 Gy for 15 MeV protons and 3.1 Gy
for 12 MeV protons and is comparable to the typical dose per fraction for a
clinical treatment but delivered in a single pulse.
4. Discussion and conclusions
The CCAP has proposed a concept for a new facility to perform detailed
systematic studies of cell irradiation. The facility will use novel accelerator
technologies to deliver intense beams of protons and ions from helium to car-
bon. The optics design of the beam-line for the first stage of LhARA has been
verified by comparing the beam envelope calculations from BeamOptics with
particle tracking simulations using BDSIM and these show good agreement.
The energy deposition profile in the end station has also been investigated
and this shows that for the current design, 15 MeV is a good choice for the
15
Figure 12: Comparison of the beta functions in the 90◦ bend region.
laser cut-off energy allowing irradiating the cells before and within the region
of the Bragg peak.
In these simulations, space charge effects have not been included since
BDSIM does not include this effect as it is based on Geant4 which is a
single-particle tracking code. This is clearly an important issue for the high-
intensity bunches produced by the laser system and the capture system.
Verification of these results will be done using a different simulation tool
that includes space charge effects.
Further work is on-going to finalise the design of LhARA including: up-
dating the BDSIM simulations with input beams generated directly from
EPOCH simulations; improving the description of the Gabor lens in BDSIM
using a 3D electro-magnetic field map; investigating a more compact beam
transport channel; and designing LhARA Stage II that will include a post-
accelerator to deliver higher beam energies for in vivo studies with protons
and in vitro studies with heavier ions.
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Figure 13: Distribution of the x phase space of the beam at the entrance of the end station.
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Figure 14: Distribution of the y phase space of the beam at the entrance of the end station.
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Figure 15: Distribution of the x-y profile of the beam at the entrance of the end station.
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Figure 16: Energy loss as a function of depth in the end station for three different beam
energies 10 MeV, 12 MeV and 15 MeV. For each beam energy 1 × 104 particles were sim-
ulated. The strip below the graph shows the material composition of the end station to
scale.
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